BMR Medical and Senai Institute for Innovation in Electrochemistry have partnered to create the low-cost, fully disposable electrochemical biosensor for HER2 detection. Read G1's full article.
This new technology will simplify the diagnosis of very aggressive breast cancer. According to the WHO (World Health Organization) Her2-positive breast cancer is found in approximately 20% of patients and expresses metastatic disease in approximately 30% of cases, affecting 120,000 women per year worldwide.
“This is a beautiful project with the potential to greatly simplify the diagnosis and monitoring of breast cancer treatment, contributing to BMR Medical's raison d'être: #firstopatient. The innovation proposed by the project brings the prospect of popularizing the diagnosis of the type of cancer with the highest incidence and mortality, among women, in Brazil and in the world, with the possibility of anticipating the diagnosis, which makes early treatment possible and increases the chance of disease cure. We are very proud of the partnership with Senai, which brings with it technical professionals of the highest caliber. The partnership with Senai is in line with BMR Medical's DNA: we work with passion and integrity, innovating to take care of people”, celebrates Patricia Zancanella, Quality and Regulatory Affairs coordinator at BMR Medical.
